



Recognizing Risk Factors for Breast Cancer-Related Lymphedema (BCRL)

Overview

Breast cancer-related lymphedema (BCRL)

is a chronic, sometimes debilitating complication of treatment for breast cancer, impacting 5–40% of patients depending on their individual risk profile. Early identification of at-risk patients enables regular surveillance, education, and timely intervention, dramatically reducing overall severity and incidence.^{[1][2][3]}



MAJOR TREATMENT-RELATED RISK FACTORS

- **Axillary Lymph Node Dissection (ALND):** The strongest single risk factor; having more lymph nodes removed (10 or more) significantly increases risk (20–53% risk with ALND vs. 5–17% with sentinel node biopsy).^[1]
- **Postoperative Radiotherapy:** Regional lymph node radiation increases relative risk by 1.8–2 times, especially when combined with ALND.^{[4][1]}
- **Postoperative Wound Complications:** Wound infection or axillary lymphocele multiplies odds 3–4 fold.^[1]
- **Neoadjuvant Chemotherapy:** Neoadjuvant chemotherapy is increasingly recognized as a risk factor, with contemporary studies showing it adds to risk.^{[2][3][5][1]}

PATIENT AND DISEASE-RELATED RISK FACTORS

- **High Body Mass Index (BMI ≥ 30):** Obesity nearly quadruples risk; 32% of obese patients develop BCRL vs. 10.5% with BMI < 30 .^{[6][5][1]}
- **Hypertension and Diabetes:** These comorbidities are associated with higher risk, though evidence is variable.^{[5][6]}
- **Advanced Breast Cancer Stage (Stage III):** Patients with advanced disease have 1.7 times higher risk compared to those with early-stage disease.^{[2][1]}
- **Race:** Black and other minoritized populations have a higher risk of lymphedema, independent of other factors. Studies show disparities in prevalence and outcomes, emphasizing a need for tailored patient education and surveillance.^{[5][2]}
- **Genetic Predispositions:** Variations in certain genes and biomarkers may increase individual risk, suggesting personalized approaches in the future.^[2]



ADDITIONAL CONSIDERATIONS

- **Chemotherapy and Neoadjuvant Therapy:** Systemic therapies are linked to increased risk, though this is lower than surgical or obesity-related risk factors.^{[5][2]}
- **Long Duration of Axillary Drainage (>7 days):** Associated with higher risk of developing BCRL.^[1]
- **Physical Strain or Injury:** Overuse, trauma, or infection of the ipsilateral arm may provoke onset.^[1]
- **Lack of Breast Reconstruction:** Some evidence suggests absence of immediate reconstruction may elevate risk.^[1]



CLINICAL HIGHLIGHTS

- Most cases develop within three years post-treatment, most commonly in the first year.^[1]
- Risk is cumulative—multiple treatment and patient factors substantially elevate likelihood.
- Early education, regular arm volume monitoring, and prompt intervention can reduce incidence and severity.^[3]
- If a patient has any of these risk factors, initiate ongoing surveillance, regular arm volume and/or bioimpedance monitoring and empower with self-monitoring and prevention education.

ACTIONABLE SUMMARY TABLE

Risk Factor	Relative Risk (RR)/Comments
ALND (≥ 10 nodes)	20–53% Risk ^{[1][5]}
Sentinel Node Biopsy	5–17% Risk ^{[1][5]}
Radiotherapy (Regional Nodes)	RR 1.8–2 (Especially with ALND) ^{[1][4][7]}
BMI ≥ 30	4x Higher Risk ^{[6][5]}
Race (Black, Other minority)	Higher Risk, Disparities ^{[2][5]}
Stage III Disease	1.7x Higher Risk ^[1]
Infection/Wound Issues	3–4x Increased Odds ^[1]
Neoadjuvant Chemotherapy	Emerging Risk Factor ^[5]

Early identification and vigilant follow-up in at-risk groups—including multidimensional education, surveillance, and intervention—are critical to minimize the personal and clinical impact of breast cancer–related lymphedema.^{[3][2][5][1]}

References:

1. <https://pmc.ncbi.nlm.nih.gov/articles/PMC6107585/>
2. <https://ascopubs.org/doi/10.1200/JCO.19.02896>
3. <https://pubmed.ncbi.nlm.nih.gov/39438352>
4. [https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370\(24\)00020-8/fulltext](https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(24)00020-8/fulltext)
5. <https://jamanetwork.com/journals/jamaoncology/fullarticle/2793346>
6. <https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.34377>
7. <https://pmc.ncbi.nlm.nih.gov/articles/PMC5590641/>



Lymphatic Education
& Research Network

LE&RN is a 501(c)3 nonprofit organization located at 154 West 14th Street, 2nd Floor, New York, NY 10011. For more information: www.LymphaticNetwork.org

LE&RN thanks the following experts for their contributions to this document:

Geoffrey E. Hespe, MD and
Raghu P. Kataru, PhD



Memorial Sloan-Kettering
Cancer Center

Lymphedema and Lymphatic Research
Laboratory, Memorial Sloan-Kettering Cancer
Center, New York, NY

Madeleine Givant, BS and
Dhruv Singhal, MD



Beth Israel Deaconess
Medical Center

Boston Lymphatic Center, Beth
Israel Deaconess Medical Center,
Boston, MA